Target intelligence / Profile preview

Intestinal microbiota composition (None established)

Target: None established
Molecular classification: Other (Ecological community/consortium), Not classified under standard molecular families such as receptors, enzymes, ion channels, etc.

Overview

The term “intestinal microbiota composition” refers broadly to the variety and relative abundance of microorganisms inhabiting the gastrointestinal tract. This includes hundreds to thousands of species from major phyla such as Bacteroidetes/Bacillota/Firmicutes/Actinobacteria/Verrucomicrobia/Pseudomonadota. These communities play critical roles in digestion/metabolism, immune regulation, protection against pathogens, vitamin synthesis and more. Disruptions (“dysbiosis”) have been linked with numerous diseases including obesity/metabolic disorders/inflammation/infection/cancer/neuropsychiatric conditions. However—as an ecological descriptor—it does not represent a discrete molecular entity suitable for direct pharmacological targeting like receptors or enzymes do.

Other names: Gut microbiotaGut floraGut microbial communityIntestinal microfloraHuman gut ecosystem

Mechanism of action

Not applicable for this entry; however: *Antibiotics*—reduce bacterial diversity/composition. *Probiotics/prebiotics*—promote growth/activity of beneficial bacteria. *Fecal transplantation*—restores healthy microbial balance after dysbiosis. These mechanisms act on populations/ecosystems rather than individual molecules.

Biological functions

Digestion of complex carbohydrates and dietary fibersSynthesis of essential vitamins (e.g., biotin, vitamin K)Regulation of immune system development and functionProtection against pathogenic microbes (colonization resistance)Production of short-chain fatty acids with anti-inflammatory effectsMaintenance of intestinal barrier integrity

Disease associations

Altered intestinal microbiota composition ("dysbiosis") has been associated with:Obesity and metabolic syndromeInflammatory bowel disease (IBD)Autoimmune diseasesInfections (e.g., Clostridioides difficile colitis)Cancer risk modulationNeuropsychiatric conditions via the gut-brain axis

Safety considerations

Unintended pathogen overgrowth after antibiotics ("opportunistic infections")Transfer/transmission risks with fecal transplantation proceduresDifficulty predicting individual responses due to high inter-individual variability in baseline compositionsLong-term consequences of altering complex ecosystems remain incompletely understood

Interacting drugs

Antibiotics (profoundly alter gut microbiota composition)

3 more in the full profile.

Biomarkers

Microbial taxa abundance ratios (such as Firmicutes/Bacteroidetes)Presence/absence of specific genera/species (Faecalibacterium prausnitzii, etc.)Short-chain fatty acid levels

Beyond the preview

Go deeper on Intestinal microbiota composition (None established).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intestinal microbiota composition (None established).

Explore the full profile